Articles tagged with Chemotherapy
A new study found that long-term testicular cancer survivors who received cisplatin-based chemotherapy experienced more severe neurological side effects compared to those not treated with chemotherapy. The study suggests that dose-intensive chemotherapy regimens can limit ototoxicity and hearing impairment in these patients.
A phase 2 trial investigates the effectiveness of a combined chemotherapy regimen of gemcitabine and oxaliplatin (GEMOX-B) plus bevacizumab in treating advanced biliary-tract cancers, showing an overall response rate of 40% and stable disease in 29%. Whole-body PET scans show promising results for monitoring treatment response.
The editorial highlights exaggerated fears and hopes in media coverage of cancer research, such as uncontrolled study results and unwarranted fear from studies. Journalists can alleviate this problem by asking the right questions, highlighting study limitations, and providing data to support claims.
Researchers have developed a new mouse variety that approximates human genetic diversity, allowing for more accurate testing of chemotherapeutic drugs. The study aims to reduce the risk of adverse reactions and improve treatment outcomes for cancer patients.
A recent study found that adding capecitabine to a standard chemotherapy regimen for breast cancer improves recurrence-free survival, but at the cost of increased adverse events. The treatment was associated with more cases of diarrhea and hand-foot syndrome, while also causing more severe neutropenia.
Scientists at Michigan State University are using a $3 million NIH grant to study the synthesis of medicinal compounds in popular plants. The goal is to understand how genes contribute to this process, leading to cheaper and more effective drug development.
A review of nearly 150 papers found that tinnitus causes significant distress, with many patients told nothing can be done to alleviate symptoms. The researchers advocate for increased support, guidance, and treatment options for those affected.
Researchers at Duke University have developed a simple and inexpensive method for loading cancer drugs into nano-scale delivery vehicles. The new formulation showed promising results in animal models, eliminating tumors after a single treatment while reducing side effects associated with systematic chemotherapy.
Researchers are developing innovative treatments to starve cancer cells of glucose, a strategy that has shown promising results in breast and colon cancer cases. RNA interference is also being explored as a gene therapy approach to block genes involved in cancer growth, with significant progress made in administering these medicines.
Combining chemotherapy with radiotherapy more than doubles event-free survival for patients with locally advanced head and neck cancer without prior surgery. Non-platinum-based chemotherapy shows long-term benefit with lower toxicity compared to platinum therapies.
Researchers found that leukemia cells reliant on MCL-1 are more sensitive to chemotherapeutic drugs than those dependent on BCL-2. A block in apoptosis selected during oncogenesis can significantly impact cancer's response to chemotherapy.
A team of University of Alberta researchers successfully synthesized a natural substance called Palmerolide A, which shows exceptional potential to specifically treat melanoma. The potency of palmerolide is exceptional and may prove to be more effective with less toxicity than current chemotherapy approaches.
Research reveals that up to a quarter of testicular cancer survivors experience long-term neurological, hearing, and circulation problems, as well as a higher risk of secondary cancers. However, many survivors can successfully father children after treatment, with up to 80% successful pregnancies.
Researchers found that a multivariable prediction model can accurately identify patients at low risk of recurrence, allowing for reduced chemotherapy treatments without compromising patient outcomes. The study suggests personalized medicine approach could improve cancer treatment decisions.
Researchers at Northwestern University discovered a potent new chemotherapy cocktail that inhibits breast cancer cell invasion by half. The mix of dasatinib and doxorubicin targets the Src kinase enzyme, believed to play a key role in breast cancer metastasis.
A phase 2 study found that adding imatinib mesylate to regular chemotherapy increased three-year survival rates for children with Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) from 30-35% to 87%. The drug was well-tolerated and showed no significant side effects.
A new approach to treating malignant brain tumors has been discovered, with chemotherapy alone proven to be just as effective as traditional radiation therapy. The study identified a key gene mutation called IDH1 that predicts a better prognosis for patients, regardless of treatment.
Masitinib targets mast cells and shows greater activity and selectivity against KIT than benchmark TKI imatinib. The study demonstrates masitinib's potential in treating KIT and PDGFR-dependent diseases, including various cancers, inflammatory diseases, and neurological indications.
Researchers discover a drug that inhibits TAK-1 enzyme, making pancreatic cancer cells sensitive to chemotherapy. The combination of the drug with classic anti-cancer drugs shows significant tumor reduction and increased survival rates in mice.
A new study found that investing in colorectal cancer screening programs could reduce treatment costs by more than half. The study suggests that the increasing use of expensive cancer drugs will make screening programs more cost-effective, making them a desirable investment for governments and insurance companies.
A phase I extension study has shown that 64% of patients with the BRAF mutation experienced partial response to a new compound, with rapid and dramatic shrinking of metastatic tumours. The treatment has fewer side effects compared to standard chemotherapy and is being explored as part of larger trials.
A new study found that targeted heat therapy significantly improves overall survival and reduces cancer recurrence in patients with locally advanced soft tissue sarcomas. The treatment, which involves heating the tumor to kill cancer cells, also makes chemotherapy more effective and improves blood flow.
A Purdue University researcher developed a fiber-optic sensor capable of measuring oxygen intake rates in real-time. The self-referencing optrode has broad applications across disciplines, including biomedical science, agriculture, and material science.
New research finds that adding cetuximab to chemotherapy reduces the risk of death from advanced non-small cell lung cancer by 13%, while also slowing disease progression and increasing the chance of tumor shrinkage. The study, which included over 2,000 patients, also found a 10% improvement in progression-free survival.
A randomized phase III study found that pemetrexed significantly improved progression-free survival (4.3 months vs 2.6 months) and overall survival (13.4 months vs 10.6 months) compared to placebo in patients with advanced non-squamous NSCLC who did not progress after initial platinum-based chemotherapy.
A phase III randomised controlled trial found that dose-dense weekly paclitaxel plus carboplatin improved survival in women with advanced epithelial ovarian cancer, with a median progression-free survival of 28 months compared to 17 months. Overall survival at 3 years was also higher in the dose-dense regimen group.
A new once-daily medication has shown to be as effective as multiple dosings for treating the most common mouth infection in HIV/AIDS patients. The treatment, a small tablet applied daily, provides relief from oral candidiasis (OC) with few or no side effects.
A new treatment protocol using dexamethasone instead of prednisone and less intensive chemotherapy showed similar event-free survival in non-high risk patients but better results in high-risk patients, reducing the risk of side effects. Overall, the treatment strategy improved survival rates for children with acute lymphoblastic leukemia.
American mayapple, a common weed in US, contains high podophyllotoxin levels, offering potential for commercial production of anti-cancer compound. Researchers identify eastern US colonies with high podophyllotoxin content, paving the way for development of high-value crop.
A Phase II study shows Avastin significantly increases response rates, progression-free survival times and survival rates in patients with recurrent glioblastoma. The treatment was found to be effective both alone and in combination with chemotherapy, improving patient outcomes and quality of life.
A study found that chemotherapy impairs sleep-wake activity rhythms in breast cancer patients, leading to shorter days and disrupted biological clocks. The disruption worsens with repeated chemotherapy cycles, highlighting the need for routine screening and management of sleep disturbances.
A new tumor marker has been identified for brain tumor resistance, allowing for targeted therapy approaches. The discovery of a
Researchers found that nadroparin almost halves the risk of developing blood clots in ambulatory cancer patients receiving chemotherapy. The study, published in The Lancet Oncology, showed a significant reduction in thromboembolic events in patients treated with nadroparin compared to those receiving placebo.
Researchers at University of Utah Health have made a surprising connection between high levels of GSTM4 protein and poor chemotherapy response in Ewing's sarcoma patients. The study suggests that targeting GSTM4 could lead to more effective treatments for individual patients.
Researchers found that a key protein called Fbx6 helps eliminate activated Chk1, but defects in this process can lead to chemotherapy resistance. By understanding how cancer cells respond to Chk1 degradation, scientists may develop new treatments with fewer side effects.
A research team led by Professor Patrick Gunning at the University of Toronto has developed molecules that inhibit Stat3, a protein involved in almost all cancers. These inhibitors show selectivity against cancer cells but not healthy cells, offering potential for improved chemotherapy efficacy and reduced side effects.
Scientists at Dana-Farber Cancer Institute have discovered the mechanism behind a DNA repair-blocking approach to cancer treatment, suggesting that these drugs can sensitize cancer cells to chemotherapy. The findings also indicate that normal cells may be protected from DNA damage by these inhibitors.
New research by MIT cancer biologists shows that tumor mutations can predict chemotherapy success. Genetic profiling of tumors can help doctors tailor treatments to each patient. The study identified specific genes and their interactions to determine how well cancer cells respond to chemotherapy.
New commentary published in JNCI Journal of the National Cancer Institute discusses treatment options for metastatic breast cancer. The European School of Oncology Metastatic Breast Cancer Task Force recommends sequential chemotherapy with a single agent for patients without rapid progression or life-threatening metastasis.
Researchers found that combination therapies tailored to patient prognosis improved patient outcomes and increased five-year, disease-free survival rates. Prophylactic cranial irradiation was shown to significantly decrease the risk for brain metastases in NSCLC patients.
Studies presented at the WCLC confirm that targeted therapies have improved efficacy and prolonged progression-free survival time compared to chemotherapy. Patients with EGFR mutations who received gefitinib experienced longer progression-free survival and greater objective response rates, while erlotinib showed prolonged progression-f...
A novel immunoconjugate targeting EphA2 protein shows substantial antitumor activity in ovarian cancer cell lines and mice. The agent inhibits tumor growth by 85% compared to control, with significant effects on proliferation and apoptosis.
Researchers developed a novel therapeutic delivery system that targets EphA2 protein in ovarian cancer cells, delivering chemotherapy with high specificity and reducing tumor growth by up to 98%. The therapy shows promising results in preclinical models and is expected to enter phase I clinical trials soon.
Researchers from Université de Montréal and McGill University have engineered an enzyme that resists harmful agents like methotrexate, a breakthrough in treating genetic diseases. The study's discovery provides new avenues for therapies to combat conditions like leukemia.
A new trial shows that chemotherapy plus radiotherapy, either with or without surgery, are viable options for patients with stage IIIA (N2) non-small-cell lung cancer. The treatment improved overall survival and progression-free survival rates compared to standard concurrent chemotherapy and radiotherapy alone.
A study by MU researchers found that cancer survivors experience mild decreases in skills like verbal fluency and problem-solving ability, impacting their daily lives. The researchers identified specific interventions, such as pharmaceuticals and cognitive behavior techniques, to help patients manage these challenges.
Scientists at Stanford University School of Medicine have created fluorescent probes that can noninvasively image apoptosis in living tumors, allowing for the gauge of treatment effectiveness. The probes bind exclusively to caspases, enzymes regulating cell death, and respond with light emission, highlighting dying cells.
A new chemotherapy regimen, ABVE-PC, has been identified as a successful treatment for pediatric Hodgkin lymphoma, reducing long-term risks and improving survival rates. The treatment delivers dose-dense drug delivery while minimizing cumulative doses, resulting in lower toxicity and improved outcomes.
A study by Columbia University's Mailman School of Public Health found that elderly women with localized breast cancer are less likely to receive chemotherapy, with only 15% receiving treatment. In contrast, younger women with nonmetastatic breast cancer received adjuvant chemotherapy at a rate of 70%.
A new study from the University of Michigan Comprehensive Cancer Center found that a single round of chemotherapy can identify patients most likely to benefit from preserving their speech. After three years, 78% of T4 study participants were still alive and 58% had an intact larynx.
Survival rates for placental-site trophoblastic tumours (PSTTs) vary depending on how long ago the related pregnancy occurred. The study found that patients with stage I disease had a 10-year probability of overall survival of 90%, while those with recurrent disease or disease resistant to treatment had poor survival.
The report emphasizes the importance of identifying specific types of breast cancer and tailoring treatment to individual patients. It recommends adjuvant endocrine therapy for most patients with oestrogen receptor-positive tumours, anti-HER2 therapy for HER2-positive disease, and chemotherapy for triple-negative disease.
Researchers design a minimally invasive system combining ultrasound and chemotherapy to target brain tumors without surgery or radiation. The approach aims to provide real-time imaging and localized temperature increases to melt liposome shells and release chemotherapy directly to the tumor.
UCF researcher J. Manuel Perez's nanoparticles could potentially replace chemotherapy with targeted cancer treatment. The nanoparticles, carrying Taxol and other molecules, selectively target cancer cells while leaving healthy tissue intact.
Researchers found that applying a chemotherapy medication to the face reduced actinic keratoses by 87% and improved signs of aging. The treatment also showed promise in addressing photo-aging, with patients reporting improved skin appearance and willingness to undergo therapy again.
A study from Northwestern University found that Cremophor-based paclitaxel caused life-threatening allergic reactions in 38% of patients, leading to 109 deaths. The solvent is believed to trigger severe reactions, even in patients with premedication.
The I-SPY trial offers critical insights into locally advanced breast cancer, emphasizing the importance of not ignoring growing breast masses. The study found that most interval cancers are discovered between routine mammogram exams, suggesting a need for better screening strategies.
Researchers identified a way to boost cisplatin's effectiveness by targeting DNA repair proteins in cancer cells. Attenuating the function of RAD50 protein complex sensitizes human tumor cells to cisplatin-based chemotherapy.
Researchers found that adding gefinitib to standard chemotherapy improved tolerability in advanced head and neck cancer patients, but did not increase survival rates. The combination therapy showed potential in delaying the spread of the disease.
A new study reveals that combining chemotherapy agents with 5FU increases disease-free survival for patients under 70, but does not provide similar benefits for those aged 70 and older. The research found that the aggressive treatment strategy is better tolerated by younger patients, while older patients may experience more side effects.